<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00738140</url>
  </required_header>
  <id_info>
    <org_study_id>07-081</org_study_id>
    <nct_id>NCT00738140</nct_id>
  </id_info>
  <brief_title>Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors</brief_title>
  <official_title>Lifestyle Intervention to Improve Insulin Sensitivity and Markers of Cardiovascular Risk in Prostate Cancer Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to discover if intensive lifestyle changes (such as diet and&#xD;
      increased physical activity) improve the body's sensitivity to insulin, and therefore help&#xD;
      prevent diabetes and other cardiovascular disease, in men receiving GnRH hormone therapy for&#xD;
      prostate cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  In this study, participants will be divided into two groups. One group will undergo&#xD;
           intensive lifestyle changes (Lifestyle Intervention Group) designed by the Diabetes&#xD;
           Prevention Group, and the other (Control Group) will follow the guidelines for healthy&#xD;
           living established by the Food Guide Pyramid and the National Cholesterol Education&#xD;
           Program.&#xD;
&#xD;
        -  All visits will take place at the General Clinical Research Center at the Massachusetts&#xD;
           General Hospital.&#xD;
&#xD;
        -  At the initial visit, the following will be performed: Bionutrition evaluation; Oral&#xD;
           Glucose Tolerance Test (OGTT); additional blood work and; Dual Energy X-Ray&#xD;
           Absorptiometry (DXA) Scan.&#xD;
&#xD;
        -  After the initial visit, visits will be scheduled at 3, 6 and 12 months after and the&#xD;
           above procedures will be repeated.&#xD;
&#xD;
        -  Participants will be randomized into one of the two study groups. Lifestyle Intervention&#xD;
           Group: The goal for participants assigned to this group are to achieve and maintain a&#xD;
           weight loss of at least 7% of initial body weight through a healthy low calorie, low fat&#xD;
           diet and to engage in physical activity of moderate intensity. Control Group:&#xD;
           participants in this group will receive standard nutrition and exercise recommendations&#xD;
           from the Food Guide Pyramid and the National Cholesterol Education Program Step 1 diet&#xD;
           to reduce body weight and increase physical activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the effect of intensive lifestyle modification on insulin sensitivity in men receiving GnRH agonist therapy for prostate cancer.</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the effects of intensive lifestyle modification on other markers of cardiovascular disease risk.</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intensive lifestyle intervention based on the Diabetes Prevention Program</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Will follow the guidelines for healthy living established by the Food Guide Pyramid and the National Cholesterol Education Program</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diabetes Prevention Program</intervention_name>
    <description>12-lesson program which will cover diet, exercise, and behavior modification.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed prostate cancer&#xD;
&#xD;
          -  Current Hormone therapy with GnRH agonist of 3 months or longer&#xD;
&#xD;
          -  Overweight or obese (body mass index of 25kg/m2 or greater)&#xD;
&#xD;
          -  No other conditions that prevent intensive lifestyle intervention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of diabetes mellitus requiring drug therapy&#xD;
&#xD;
          -  Hemoglobin Aic of 7% or greater&#xD;
&#xD;
          -  Symptomatic metastatic disease&#xD;
&#xD;
          -  Myocardial infarction within 6 months&#xD;
&#xD;
          -  Treatment with anabolic agents or metabolic agents known to affect insulin or glucose&#xD;
             levels&#xD;
&#xD;
          -  Disease progression according to PSA Working Group Criteria&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Smith, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>June 23, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2008</study_first_posted>
  <last_update_submitted>July 9, 2013</last_update_submitted>
  <last_update_submitted_qc>July 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Matthew R. Smith, MD, PhD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>insulin sensitivity</keyword>
  <keyword>Diabetes Prevention Program</keyword>
  <keyword>lifestyle intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

